[Minimal residual disease in chronic myeloid disease. A practical focus].
Casado
L F
LF
Servicio de Hematología, Hospital Virgen de la Salud, Toledo.
Steegmann
J L
JL
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015139:Blotting, Southern; D016026:Bone Marrow Transplantation; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D015321:Gene Rearrangement; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D009363:Neoplasm Proteins / Q000032:analysis; D018365:Neoplasm, Residual; D015513:Oncogene Proteins / Q000235:genetics; D010677:Philadelphia Chromosome; D016133:Polymerase Chain Reaction; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D051562:Proto-Oncogene Proteins c-bcr
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D009363:Neoplasm Proteins; D015513:Oncogene Proteins; D011518:Proto-Oncogene Proteins; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; C496613:BCR protein, human; D051562:Proto-Oncogene Proteins c-bcr